Literature DB >> 20555059

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

G D'Addario1, M Früh, M Reck, P Baumann, W Klepetko, E Felip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20555059     DOI： 10.1093/annonc/mdq189

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  116 in total

1.  Anti-tumor effect of cactus polysaccharides on lung squamous carcinoma cells (SK-MES-1).

Authors:  W Li; D Wu; B Wei; S Wang; Hx Sun; Xl Li; F Zhang; Cl Zhang; Y Xin
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-08-23

2.  Octamer transcription factor-1 induces the Warburg effect via up-regulation of hexokinase 2 in non-small cell lung cancer.

Authors:  Zhen Li; Jin Su; Mingming Sun; Jiaqi Song; Huanran Sun; Jun Fan; Guo Chen; Changliang Shan; Qi Qi; Shuai Zhang
Journal:  Mol Cell Biochem       Date:  2021-05-10       Impact factor: 3.396

3.  Just another abdominal pain? Psoas abscess-like metastasis in large cell lung cancer with adrenal insufficiency.

Authors:  Vera Bernardino; Luis Silva Val-Flores; João Lopes Dias; Luís Bento
Journal:  BMJ Case Rep       Date:  2015-06-10

4.  The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.

Authors:  Chen Lin; Shanshan Wang; Weiwei Xie; Jianhua Chang; Yu Gan
Journal:  Cancer Biol Ther       Date:  2015-05-15       Impact factor: 4.742

5.  Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.

Authors:  Jingwei Jiang; Xiaohua Liang; Xinli Zhou; Ruofan Huang; Zhaohui Chu; Qiong Zhan
Journal:  J Cancer Res Clin Oncol       Date:  2012-08-05       Impact factor: 4.553

Review 6.  The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.

Authors:  Arijit Ganguli; Phillip Wiegand; Xin Gao; John A Carter; Marc F Botteman; Saurabh Ray
Journal:  Qual Life Res       Date:  2012-07-18       Impact factor: 4.147

Review 7.  Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

8.  Knockdown of EIF5A2 inhibits the malignant potential of non-small cell lung cancer cells.

Authors:  Cheng Chen; Bojia Zhang; Shanshan Wu; Yongxiang Song; Jian Li
Journal:  Oncol Lett       Date:  2018-01-22       Impact factor: 2.967

9.  Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

Authors:  Analia Rodríguez Garzotto; C Vanesa Díaz-García; Alba Agudo-López; Elena Prieto García; Santiago Ponce; José A López-Martín; Luis Paz-Ares; Lara Iglesias; M Teresa Agulló-Ortuño
Journal:  Med Oncol       Date:  2016-08-27       Impact factor: 3.064

10.  Results of platinum-based chemotherapy in unselected performance status (PS) 2 patients with advanced non-small cell lung cancer: a cohort study.

Authors:  Stéphane Jouveshomme; Florence Canoui-Poitrine; Aurélie Le Thuaut; Sylvie Bastuji-Garin
Journal:  Med Oncol       Date:  2013-03-28       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.